Advances in Clinical, Diagnostic and Neurosurgical Management in Pediatric Neuro-Oncology

Dear Colleagues,

Advances in the molecular understanding of pediatric central nervous system tumors over the last two decades have resulted in enhanced tumor classifications, molecular-based targeted therapies, neurosurgical diagnostic and therapeutic technologies, immune-based therapies, neuroimaging capabilities, and novel radiation therapy approaches.  The pediatric neuro-oncology revolution has resulted in how we diagnose, risk-stratify, and treat children and young adults with newly diagnosed and recurrent central nervous system tumors.

This Special Issue is focused on how recent advances in pediatric neuro-oncology influence the clinical, diagnostic, and neurosurgical aspects of patient care.

A molecular-targeted treatment-based approach has led to novel biologic and immune-based therapies, each with their own central nervous system and systemic toxicity profiles. The use of robotic guided biopsy and laser ablation has provided an alternative to conventional approaches and are associated with both opportunities and risks. Proton therapy, radiosurgery, and re-irradiation are increasingly being utilized in the management of newly diagnosed and recurrent central nervous system tumors and are associated with unique neuroradiographic features which make distinguishing progression from pseudo progression challenging. The emerging role of radio-genomics in pediatric neuro-oncology may enhance diagnosis, prognostication and influence treatment decisions.  Novel therapeutic and technological advances in pediatric neuro-oncology have influenced the clinical and neurosurgical decision making and management of patients with implications in both the upfront and late effects setting.

Prof. Dr. John Ross Crawford
Prof. Dr. Michael Levy
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.